Redman B G, Hillman G G, Flaherty L, Forman J, Dezso B, Haas G P
Division of Hematology-Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, Michigan 48201, USA.
Clin Cancer Res. 1998 Feb;4(2):283-6.
We have previously demonstrated that local tumor irradiation effectively enhanced the therapeutic effect of interleukin 2 (IL-2) therapy in an experimental murine renal adenocarcinoma model. Based on these preclinical studies, we have designed and initiated a Phase II trial of irradiation combined with IL-2 for the treatment of metastatic renal cell carcinoma. Patients received 800 cGy to the primary or metastatic lesions on days 1 and 15 followed by IL-2 (600,000 IU/kg i.v.) every 8 h on days 4-8 and 18-22. Sixteen patients were entered; all completed treatment and are therefore evaluable for toxicity and response. Two partial remissions were seen for a response rate of 12.5% (95% confidence interval, 0-28.7). There was no increase in toxicity over that which is anticipated from IL-2 alone. The antitumor activity seen in this trial is consistent with what would be expected from high-dose IL-2 alone.
我们之前已经证明，在实验性小鼠肾腺癌模型中，局部肿瘤照射可有效增强白细胞介素2（IL-2）治疗的疗效。基于这些临床前研究，我们设计并启动了一项关于照射联合IL-2治疗转移性肾细胞癌的II期试验。患者在第1天和第15天接受针对原发或转移病灶的800 cGy照射，随后在第4 - 8天和第18 - 22天每8小时静脉注射IL-2（600,000 IU/kg）。16名患者入组；所有患者均完成治疗，因此可评估毒性和反应。观察到2例部分缓解，缓解率为12.5%（95%置信区间，0 - 28.7）。与单独使用IL-2预期的毒性相比，并未增加。该试验中观察到的抗肿瘤活性与单独使用高剂量IL-2预期的结果一致。
